DeepMed Research

NT-219

Generic Name: NT-219

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₄BrNO_₅S

CAS Number: 1198078-60-2

Unique Ingredient Identifier: K1WT1A1UP5

Advanced Drug Monograph

Access comprehensive pharmacological analysis, clinical applications, and therapeutic considerations.

Clinical Trials

NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Phase 1

Not yet recruiting

Conditions: Head and Neck Cancer
Head and Neck Squamous Cell Carcinoma

Interventions: Drug: NT219

First Posted Date: 2025-04-09

Last Posted Date: 2025-05-08

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 29

Registration Number: NCT06919666

Locations: 🇺🇸
Universtiy of Colorado Hospital, Aurora, Colorado, United States
🇺🇸
UCHealth Highlands Ranch Hospital, Highlands Ranch, Colorado, United States

A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer

Phase 1

Active, not recruiting

Conditions: Squamous Cell Carcinoma of Head and Neck
Colorectal Adenocarcinoma
Head and Neck Cancer
Solid Tumor, Adult
Metastatic Solid Tumor
Recurrent Solid Tumor

Interventions: Drug: NT219
Drug: NT219 and ERBITUX® - Dose Escalation
Drug: NT219 and ERBITUX® - Expansion

First Posted Date: 2020-07-16

Last Posted Date: 2024-05-09

Lead Sponsor: TyrNovo Ltd.

Target Recruit Count: 110

Registration Number: NCT04474470

Locations: 🇺🇸
California Cancer Associates for Research and Excellence, Encinitas, California, United States
🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸
UCSD Moores Cancer Center, San Diego, California, United States

and more 7 locations

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy